This paper explores the historical record in the development and deployment of vaccines globally and puts the COVID-19 vaccine rollout in that context. Although far more can be done and should be done to speed equitable access to vaccines in the COVID-19 response, it is worth noting the revolutionar...

Providing patients with high-quality essential medicines requires a well-functioning procurement, distribution, and regulatory system. However, in many low- and lower-middle-income countries (LMICs), public sector supply chain performance is far from optimal, resulting in frequent stockouts at healt...

Between 2011 and 2016, the Affordable Medicines Facility-Malaria (AMFm) subsidy program substantially increased access to WHO prequalified artemisinin combination therapies (ACTs) through Africa’s private sector pharmacies and drug-sellers. While the program was rigorously and extensively evaluated,...

Millions Saved (2016) is a new edition of detailed case studies on the attributable impact of global health programs at scale. As an input to the book, this paper provides an independent assessment of the cost-effectiveness of a selection of the cases using ex post information from impact evaluation...

Since 2001, an aid consortium known as Gavi has accounted for over half of vaccination expenditure in the 75 eligible countries with an initial per capita GNI below $1,000. 

As Latin American countries seek to expand the coverage and benefits provided by their health systems under a global drive for universal health coverage (UHC), decisions taken today – whether by government or individuals – will have an impact tomorrow on public spending requirements.&nbs...

Across multiple African countries, discrepancies between administrative data and independent household surveys suggest official statistics systematically exaggerate development progress. We provide evidence for two distinct explanations of these discrepancies.